الفهرس 
Impact of IL28B gene polymorphism on the outcome of living donor liver transplantation
AbstractOnly 14 pages are availabe for public view
 |  | from | 145 |  |  |
| | | from | 145 | | |
Abstract
Background & Aim : Recent studies have described a major impact of the IL28B gene polymorphism on the natural course and outcome of antiviral therapy in chronic hepatitis C. Our study aims to investigate the impact of IL28B of donors and recipients on the outcome of liver transplantation due to end stage HCV related liver disease, and the impact of IL28B genotypes on the response to treatment with INF based therapy or DAA.Methods: Donor and recipient IL28B rs12979860C>T single nucleotide polymorphisms (SNPs) were determined in 24 patients who had undergone LT for HCV-induced end stage liver disease and received regular follow up evaluations for two years post liver transplantation, 10 of whom were treated with pegylated interferon-a (PEG-IFN-a) and ribavirin, and 14 were treated with DAA. IL28B genetic polymorphisms were correlated with the outcome of liver transplantation and treatment response of recurrent hepatitis C.Results: We found that the CC genotype frequency was reduced among patients with HCV related end stage liver disease while, in contrast, the frequency of CT & TT increased. We also found that the donor rs12979860 CC genotype was strongly associated with the success of PEG-IFN-Ü and ribavirin treatment of recurrent hepatitis C. No association was noted between IL 28B polymorphism and fibrosis progression or patient and graft survival, and as well as liver outcomes. No impact of IL 28B polymorphism on the response to anti viral treatment (AVT) by direct acting antiviral (DAA) agents, as all different IL 28B genotypes and different recipient/donor patterns eventually achieved SVR even in cases with two unfavorable non-CC genotypes in both recipients and donors